NPPB and heart failure: Preliminary results obtained at 24 weeks follow up (71 patients in each study group) did not show any significant signal in either the primary (reduction in plasma NT-proBNP) or the secondary (worsening heart failure) endpoints (results presented at the 2022 European Society of Cardiology–Heart Failure congress).